Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.

@article{Frankfort2007IdentificationOR,
  title={Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.},
  author={Suzanne V. Frankfort and Bregje A. Appels and Antonius de Boer and Linda R. Tulner and Jos Pcm van Campen and Cornelis H. W. Koks and Jos H. Beijnen and Ben A. Schmand},
  journal={Pharmacoepidemiology and drug safety},
  year={2007},
  volume={16 5},
  pages={
          545-51
        }
}
PURPOSE Presently, it is unclear which patients suffering from Alzheimer's Disease (AD) respond to rivastigmine and if rivastigmine acts on specific cognitive domains. The aims of this study are thus to investigate treatment effects of rivastigmine on specific cognitive domains and to find possible responsive subpopulations to rivastigmine cognitive effects. METHODS Mini Mental State Examination (MMSE) and Cambridge Cognitive Examination (CAMCOG) were administered at baseline and after 6… CONTINUE READING